JP2015529217A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529217A5
JP2015529217A5 JP2015530496A JP2015530496A JP2015529217A5 JP 2015529217 A5 JP2015529217 A5 JP 2015529217A5 JP 2015530496 A JP2015530496 A JP 2015530496A JP 2015530496 A JP2015530496 A JP 2015530496A JP 2015529217 A5 JP2015529217 A5 JP 2015529217A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heteroaryl
heterocyclyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015530496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529217A (ja
JP6297570B2 (ja
Filing date
Publication date
Priority claimed from GBGB1216018.0A external-priority patent/GB201216018D0/en
Application filed filed Critical
Publication of JP2015529217A publication Critical patent/JP2015529217A/ja
Publication of JP2015529217A5 publication Critical patent/JP2015529217A5/ja
Application granted granted Critical
Publication of JP6297570B2 publication Critical patent/JP6297570B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015530496A 2012-09-07 2013-09-09 薬理活性化合物 Expired - Fee Related JP6297570B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1216018.0A GB201216018D0 (en) 2012-09-07 2012-09-07 Pharmacologically active compounds
GB1216018.0 2012-09-07
PCT/GB2013/052361 WO2014037751A1 (en) 2012-09-07 2013-09-09 Pharmacologically active compounds

Publications (3)

Publication Number Publication Date
JP2015529217A JP2015529217A (ja) 2015-10-05
JP2015529217A5 true JP2015529217A5 (enExample) 2017-11-09
JP6297570B2 JP6297570B2 (ja) 2018-03-20

Family

ID=47137118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015530496A Expired - Fee Related JP6297570B2 (ja) 2012-09-07 2013-09-09 薬理活性化合物

Country Status (6)

Country Link
US (3) US9334286B2 (enExample)
EP (1) EP2892890B1 (enExample)
JP (1) JP6297570B2 (enExample)
ES (1) ES2655026T3 (enExample)
GB (1) GB201216018D0 (enExample)
WO (1) WO2014037751A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216018D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
WO2018234778A1 (en) * 2017-06-20 2018-12-27 The Institute Of Cancer Research: Royal Cancer Hospital METHODS AND MEDICAL USES
KR102777989B1 (ko) * 2017-11-30 2025-03-12 한미약품 주식회사 4-아미노-N-(1-((3-클로로-2-플루오로페닐)아미노)-6-메틸이소퀴놀린-5-일)티에노[3,2-d]피리미딘-7-카르복사미드의 염, 및 그의 결정질 형태
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN112174903B (zh) * 2019-07-01 2022-07-12 清华大学 Tlr8的小分子调节剂
CA3156268A1 (en) * 2019-10-01 2021-04-08 Goldfinch Bio, Inc. CDK5 SUBSTITUTE 1,6-NAPHTYRIDINE INHIBITORS
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
CA3240400A1 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
CN116410189B (zh) * 2021-12-30 2024-08-06 中国科学院上海药物研究所 一种嘧啶并吡啶类化合物及其药用组合物和应用
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Impdh酵素のインヒビターであるアミノ核誘導化合物
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
WO2001055147A1 (en) 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002009036A2 (en) 2000-07-21 2002-01-31 The Trustees Of Columbia University In The City Of New York Method and apparatus for reducing distortion in images
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002324450A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
RU2301233C2 (ru) 2002-03-07 2007-06-20 Ф.Хоффманн-Ля Рош Аг Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
PL376751A1 (pl) 2002-11-12 2006-01-09 Abbott Laboratories Bicykliczne podstawione aminy jako ligandy receptora histaminowego-3
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 S1p受容体結合能を有する化合物およびその用途
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
WO2008079988A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
EP2183254B1 (en) 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
CN102596946B (zh) 2009-08-05 2015-06-17 港大科桥有限公司 抗病毒化合物及其制备和使用方法
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
ES2539972T3 (es) 2010-07-30 2015-07-07 Nerviano Medical Sciences S.R.L. Isoxazolo-quinazolinas como moduladores de la actividad de proteina cinasa
ES2377610B1 (es) * 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之6,6-稠合含氮雜環化合物及其用途
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
RU2591191C2 (ru) 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds

Similar Documents

Publication Publication Date Title
JP2015527387A5 (enExample)
JP2022522777A5 (enExample)
CN114222743A (zh) 氧代六元环并嘧啶类化合物,其制法与医药上的用途
JP2015535277A5 (enExample)
JP2014504622A5 (enExample)
JP2010524932A5 (enExample)
JP2016537382A5 (enExample)
JP2019514874A5 (enExample)
JP2012092103A5 (enExample)
JP2013545785A5 (enExample)
JP2008500997A5 (enExample)
JP2016505010A5 (enExample)
JP2015143283A5 (enExample)
JP2016506960A5 (enExample)
JP2016501250A5 (enExample)
JP2017509689A5 (enExample)
JP2017501236A5 (enExample)
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
JP2014500296A5 (enExample)
JP2019512535A5 (enExample)
JP2013532130A5 (enExample)
JP2013540712A5 (enExample)
JP2019516739A5 (enExample)
JP2017521375A5 (enExample)
JP2016528273A5 (enExample)